��«����Ƶ

��«����Ƶ has hit the ground running in 2023, announcing a key addition to its structural heart portfolio in the U.S.

Meet , the company’s latest-generation transcatheter aortic valve implantation (TAVI) system.

Navitor’s recent approval by the U.S. Food and Drug Administration not only bolsters ��«����Ƶ’s structural heart portfolio — which is the most comprehensive in the U.S.¹ — but also solidifies the company’s competitiveness in the TAVI market, the largest structural heart market, about $3 billion U.S. in 2022 and growing.²

And there’s more.

Navitor — which is designed to help open a narrowed aortic valve in people with , one of the most common and life-threatening heart valve diseases — gives physicians another minimally-invasive treatment option for people who are at a high or extreme risk for complications from open-heart surgery.

This next-gen technology follows ��«����Ƶ’s 2021 entry into the U.S. TAVI market with the TAVI system and builds on the company’s industry-leading portfolio of minimally invasive devices.

Navitor in 2021 for people in Europe with severe aortic stenosis at high or extreme surgical risk.

Adding to the momentum are on one-year outcomes showing the safety and effectiveness of Navitor for people with severe aortic stenosis.

“The FDA’s approval of Navitor is a major next step in our mission to help people live better lives through better health,” said Michael Dale, senior vice president of ��«����Ƶ's structural heart business. “The Navitor system will continue to enhance minimally invasive treatment options for people with structural heart disease and offer hope to patients who may not have other treatment choices.”

Navitor’s Competitive Advantage

��«����Ƶ’s Navitor system stands out from the competition with its unique fabric cuff that reduces or eliminates the backflow of blood around the valve frame, a common complication following TAVI procedures.

Navitor is the only self-expanding TAVI system with leaflets within the native valve, a design that can make it easier for physicians to access a person’s coronary arteries for future procedures to treat coronary artery disease. The system’s design also provides excellent blood flow through the aortic valve, which is important for cardiovascular health.

Learn more about the system and get insight on other key health technologies in the company’s new product pipeline.

References
¹Internal data at ��«����Ƶ.
²Barclays 2023 Outlook report.